Thymic Epithelial Tumor

2020 ◽  
pp. 19-64
Author(s):  
Cheng-sen Cai ◽  
Song Zhang
Keyword(s):  
Epithelial Tumor ◽  
Thymic Epithelial Tumor

scholarly journals Tumor immunity is related to 18 F‐FDG uptake in thymic epithelial tumor

2021 ◽  
Author(s):  
Hisao Imai ◽  
Kyoichi Kaira ◽  
Kosuke Hashimoto ◽  
Hiroyuki Nitanda ◽  
Ryo Taguchi ◽  
...  
Keyword(s):  
Tumor Immunity ◽  
Epithelial Tumor ◽  
Fdg Uptake ◽  
Thymic Epithelial Tumor

scholarly journals P1-125: Aberrant methylation of DAP-K, p-16, MGMT, RAR-β and HPP1 in thymic epithelial tumor

2007 ◽  
Vol 2 (8) ◽  
pp. S600
Author(s):  
Yukiko Hirose ◽  
Kazuya Kondo ◽  
Taeko Nagao ◽  
Hiroaki Toba ◽  
Takanori Miyoshi ◽  
...  
Keyword(s):  
Aberrant Methylation ◽  
Epithelial Tumor ◽  
Thymic Epithelial Tumor ◽  
P 16

Paraneoplastic myasthenia gravis: Detection of anti-MGT30 (titin) antibodies predicts thymic epithelial tumor

Neurology ◽  
1997 ◽  
Vol 49 (5) ◽  
pp. 1454-1457 ◽  
Author(s):  
R. D. Voltz ◽  
W. C. Albrich ◽  
A. Nägele ◽  
F. Schumm ◽  
M. Wick ◽  
...  
Keyword(s):  
Myasthenia Gravis ◽  
Predictive Value ◽  
Striated Muscle ◽  
Immunofluorescence Assay ◽  
Epithelial Tumor ◽  
Thymic Epithelial Tumors ◽  
Thymic Epithelial Tumor ◽  
Antibody Assays ◽  
Better Than ◽  
Titin Antibodies

It has been suggested that antibodies against nonacetylcholine receptor proteins of striated muscle are markers of the presence of a thymic epithelial tumor in patients with myasthenia gravis (MG). These antibodies may be measured using an immunofluorescence assay against striated muscle(anti-STR) or an ELISA with a recombinant 30-kd titin fragment (anti-MGT30). To directly compare anti-STR with anti-MGT30, we examined the sera of 276 consecutive patients with known or suspected MG. Definite diagnoses and thymic histology, if available, were correlated with the antibody assays. Of the 276 patients, 164 had MG. Thymic histology was obtained in 44 patients: 18 had lymphofollicular hyperplasia, 13 thymic epithelial tumors, 8 atrophy, and 5 were normal. When compared with anti-STR, anti-MGT30 showed a sensitivity of 69% (STR 77%), specificity of 100% (STR 56%, p = 0.026), negative predictive value of 82% (STR 77%), and positive predictive value of 100% (STR 56%, p = 0.003) for the identification of a thymic epithelial tumor versus thymic hyperplasia. We conclude that the anti-MGT30 ELISA is better than the anti-STR immunofluorescence assay for the diagnosis of paraneoplastic MG.

scholarly journals Perplexing Histologic Classification of Thymic Epithelial Tumor

Radiology ◽  
2015 ◽  
Vol 275 (3) ◽  
pp. 929-930 ◽  
Author(s):  
Qijun Shen ◽  
Wenchao Hu ◽  
Zhan Feng
Keyword(s):  
Epithelial Tumor ◽  
Histologic Classification ◽  
Thymic Epithelial Tumor

Mutational analysis of EGFR and KIT in thymic epithelial tumor

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 18049-18049
Author(s):  
K. Yoh ◽  
Y. Nishiwaki ◽  
G. Ishii ◽  
K. Goto ◽  
K. Kubota ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Thymic Carcinoma ◽  
Kinase Inhibitors ◽  
Mutational Analysis ◽  
Direct Sequencing ◽  
Egfr Mutations ◽  
Epithelial Tumor ◽  
Thymic Epithelial Tumor ◽  
Number Of Patients

18049 Background: Thymic epithelial tumor has been reported to express the epidermal growth factor receptor (EGFR), and thymic carcinoma has recently been described to have overexpression of KIT. We investigated the prevalence of EGFR and KIT mutations in patients with thymoma and thymic carcinoma to explore the potential for a targeted therapy with tyrosine kinase inhibitors. Methods: Genomic DNA was isolated from 41 paraffin-embedded tumor samples including 24 thymoma and 17 thymic carcinoma. EGFR mutations in exons 18, 19 and 21, and KIT mutations in exons 9, 11, 13 and 17, were analyzed by PCR and direct sequencing. Protein expressions of EGFR and KIT were also evaluated by immunohistochemistry. Results: We detected the EGFR mutation in 2 of 20 thymoma, but none of thymic carcinoma had mutation. All of the detected EGFR mutations were missense mutations in exon 21 (L858R and G863D, respectively). Expression of EGFR was seen in 71% of thymoma and 53% of thymic carcinoma. On mutational analysis of KIT, only one thymic carcinoma displayed a missense mutation in exon 11 (L576P). Expression of KIT was observed in 88% of thymic carcinoma and 0% of thymoma. Conclusions: Our findings indicate that a small number of patients with thymic epithelial tumor exhibit somatic mutations of EGFR or KIT although expressions of EGFR or KIT are present frequently in thymic epithelial tumor. Further investigations are warranted to determine their susceptibility to tyrosine kinase inhibitors in the treatment of thymoma and thymic carcinoma with EGFR or KIT mutations. No significant financial relationships to disclose.

scholarly journals A Clinical Observation of Thymic Epithelial Tumor Metastatic to Breast

Breast Care ◽  
2018 ◽  
Vol 13 (2) ◽  
pp. 133-136 ◽  
Author(s):  
Yu-Wei Deng ◽  
Yi-Wen Li ◽  
Wen-Jing Hao ◽  
Dan Lu
Keyword(s):  
Thymic Carcinoma ◽  
Color Doppler ◽  
Metastatic Breast ◽  
Stage Iv ◽  
Pathological Examination ◽  
Hematogenous Metastasis ◽  
Periodic Review ◽  
Epithelial Tumor ◽  
Term Survival ◽  
Thymic Epithelial Tumor

Background: Thymic carcinoma is prone to early metastasis and invasion, while its metastasis to the breast is particularly unique. Case Report: We describe a case of thymic epithelial tumor metastatic to the breast fulfilling clinical diagnostic criteria. A 47-year-old female patient diagnosed with stage IV thymic carcinoma and previously treated with chemoradiation was diagnosed with metastatic breast cancer during a periodic review. Color Doppler ultrasonography showed a low-echo real occupancy in the breast. Pathological examination of the breast mass confirmed the diagnosis of thymic carcinoma metastasis. Conclusion: Hematogenous metastasis of thymic carcinoma to the breast is rare but not exceptional, and long-term survival can be expected with appropriate treatment.

Sign in / Sign up

Export Citation Format

Share Document